effects of neoadjuvant chemotherapy on neuromuscular blocking agents
Conditions
Interventions
Control group:none
Combined chemotherapy group:received four cycles of doxorubicin, 5-Fu andcyclophosphamide
Combined chemotherapy andtaxol group:received four cycles of combined chemotherapy andtaxol chemotherapy respectively
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. patients aged 20-60 years old, ASA grade I-II, female breast cancer patients; 2. patients didnt receive any treatment, received four cycles of combined chemotherapy or four cycles of combined chemotherapy andfour cycles of taxol chemotherapy before the operation; 3. patients need to receive general anesthesia with neuromuscular blocking agents during the operation; 4. patients have fully understandthe nature of the study, voluntary participation in this experiment andsigned informed consent.
Exclusion criteria
Exclusion criteria: 1. patients refuse to participate the study; 2. the history of nervous system disease, mental disorder anddiabetes mellitus; 3. grade of cardiac function >=III, the history of stroke or TIA; 4. the history of cancer andchemoradiotherapy; 5. previous thoracic or abdominal surgery, upper limb surgery on the contralateral of the breast tumor; 6. liver andkidney function is not complete; 7. bronchial asthma, chronic obstructive emphysema, bronchiectasis, bullae of lung andthe history of pulmonary lobectomy; 8. neuromuscular disorder, medication history may affect the neuromuscular transmission function; 9. smoking history, pregnant woman; 10. obesity (BMI>30); 11. for any reason, the researchers believe that there is any situation that is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Train-of-four stimulation;Single-twitch stimulation; | — |
Countries
China
Contacts
Public ContactHe Zi-jing
Outcome results
None listed